Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Gaush Meditech Ltd (2407.HK)
Beijing, CN
Gaush Meditech Ltd., alongside its affiliates, is engaged in the global research, development, manufacturing, and sale of specialized medical devices for ophthalmology, serving markets both within the People's Republic of China and internationally. The company's operations are divided into four main divisions: Proprietary Products, Distribution, Technical Services, and Other Business Ventures. Its advanced ophthalmic instruments are crucial for the diagnosis, treatment, and surgical intervention of a broad spectrum of eye conditions, including vitreoretinal disorders, cataracts, glaucoma, refractive errors, ocular surface diseases, and issues in optometry and pediatric ophthalmology. The Proprietary Products division focuses on creating and producing its own line of surgical apparatus, accompanying software, intraocular lenses, and equipment for diagnosing and treating eye ailments, along with their associated consumables. Conversely, the Distribution division is responsible for selling diagnostic devices, equipment for ocular fundus examination, surgical and treatment instruments, and related consumables. The Technical Services segment provides essential support, covering warranty services, maintenance, and the supply of post-sales consumables. Lastly, the Other Business Ventures division handles equipment rental, agent registration services, and the licensing of intellectual property. Gaush Meditech Ltd. reaches its clientele—comprising public and private hospitals, among other customers—through both direct sales and a network of distributors. The company was established in 1998 and has its corporate headquarters situated in Beijing, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -8.27% | -8.62% | -6.10% | -23.06% | -46.70% | -42.11% | -21.03% | -89.80% | -90.72% | -90.72% | -90.72% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%-3.4% Q4'25: +3.1% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%+4.8% Q4'25: -4.8% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%+6.0% Q4'25: +13.6% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%+8.2% ★ Q4'25: +6.5% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%+5.1% ★ Q4'25: +10.7% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%-1.8% ★ Q4'25: -2.5% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×2.99× Q4'25: 1.76× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
1.25B
est: 1.29B (-2.5%)
|
1.41B
est: 1.40B (+0.3%)
|
1.43B
est: 1.53B (-6.5%)
|
1.38B
est: 1.56B (-11.7%)
|
1.78B
1.78B – 1.78B
+13.8% YoY
|
1.94B
1.94B – 1.94B
+9.3% YoY
|
| EBITDA |
271.91M
est: 265.37M (+2.5%)
|
374.31M
est: 289.17M (+29.4%)
|
247.31M
est: 305.62M (-19.1%)
|
169.71M
est: 312.75M (-45.7%)
|
355.88M
355.88M – 355.88M
+13.8% YoY
|
389.10M
389.10M – 389.10M
+9.3% YoY
|
| EBIT |
227.03M
est: 207.12M (+9.6%)
|
298.34M
est: 225.70M (+32.2%)
|
194.55M
est: 243.93M (-20.2%)
|
112.61M
est: 249.63M (-54.9%)
|
284.05M
284.05M – 284.05M
+13.8% YoY
|
310.56M
310.56M – 310.56M
+9.3% YoY
|
| Net Income |
-349.62M
est: 7.21M (-4,947.4%)
|
173.52M
est: 164.81M (+5.3%)
|
92.39M
est: 146.51M (-36.9%)
|
96.19M
est: 132.00M (-27.1%)
|
183.62M
183.62M – 183.62M
+39.1% YoY
|
218.24M
218.24M – 218.24M
+18.9% YoY
|
| SGA |
333.94M
est: 347.60M (-3.9%)
|
378.21M
est: 378.78M (-0.2%)
|
378.36M
est: 412.74M (-8.3%)
|
418.98M
est: 422.37M (-0.8%)
|
480.61M
480.61M – 480.61M
+13.8% YoY
|
525.47M
525.47M – 525.47M
+9.3% YoY
|
| EPS |
-3.61
est: 0.05 (-7,363.4%)
|
1.17
est: 1.14 (+3.0%)
|
0.63
est: 1.01 (-37.6%)
|
0.66
est: 0.91 (-27.4%)
|
1.27
1.27 – 1.27
+39.1% YoY
|
1.50
1.50 – 1.50
+18.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-28 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-27 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-26 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-22 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-21 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-20 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-19 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-18 | B | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-15 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-14 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-13 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-12 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-11 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-08 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-07 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-06 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-05 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-04 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-30 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-29 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-28 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-23 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-22 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-21 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-20 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-17 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-16 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 29.0K | 0.39% |
| 2 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 2.9K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Aleksey Nikolaevich Simonov | Chief Technology Officer | 3M | — |
| Alexey Nikolaevich Simonov | Chief Technology Officer | 3M | — |
| Xinwei Liu | Executive Director & Chief Executive Officer | 1M | male |
| Tieta Gao | Executive Chairman | 1M | male |
| Xinli Zhao | Executive Director & Chief Compliance Officer | 1M | male |
| Wenqi Li | Chief Financial Officer & Executive Director | 944.1K | female |
| Jianjun Zhang | Honorary President & Executive Director | 674.9K | male |
| Shui Bing Leung | Joint Company Secretary | — | female |
| Bo Zhang | Joint Company Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2407.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
